Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a proregenerative phenotype

Journal of Cell Biology

Volumn 213, Issue 2, 2016, Pages 275-288

  Capote, Joana ^a,b   Kramerova, Irina ^a   Martinez, Leonel ^a   Vetrone, Sylvia ^a,d   Barton, Elisabeth R ^c   Sweeney, H Lee ^c   Miceli, M Carrie ^a,b,c   Spencer, Melissa J ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d WHITTIER COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKEMIA INHIBITORY FACTOR; OSTEOPONTIN; SOMATOMEDIN C; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DYSTROPHINOPATHY; MACROPHAGE; MOUSE; MUSCLE CELL; MUSCLE MASS; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; C57BL MOUSE; CELL POLARITY; CYTOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; MUSCLE; PATHOLOGY; PHYSIOLOGY; REGENERATION;

ANIMALS; CELL POLARITY; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLES; MUSCULAR DYSTROPHY, ANIMAL; NATURAL KILLER T-CELLS; OSTEOPONTIN; PHENOTYPE; REGENERATION;

EID: 84969248261     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201510086     Document Type: Article

References (62)

1. Amalfitano, A., and J.S. Chamberlain. 1996. The mdx-amplification-resistant mutation system assay, a simple and rapid polymerase chain reaction-based detection of the mdx allele. Muscle Nerve. 19:1549-1553. http://dx.doi.org/10.1002/(SICI)1097-4598(199612)19:12<1549::AID-MUS4>3.0.CO;2-A
2. Arnold, L., A. Henry, F. Poron, Y. Baba-Amer, N. van Rooijen, A. Plonquet, R.K. Gherardi, and B. Chazaud. 2007. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J. Exp. Med. 204:1057-1069. http://dx.doi.org/10.1084/jem.20070075
3. Ashkar, S., G.F. Weber, V. Panoutsakopoulou, M.E. Sanchirico, M. Jansson, S. Zawaideh, S.R. Rittling, D.T. Denhardt, M.J. Glimcher, and H. Cantor. 2000. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science. 287:860-864. http://dx.doi.org/10.1126/science.287.5454.860
4. Barton, E.R., L. Morris, A. Musaro, N. Rosenthal, and H.L. Sweeney. 2002. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 157:137-148. http://dx.doi.org/10.1083/jcb.200108071
5. Barton, E.R., L. Morris, M. Kawana, L.T. Bish, and T. Toursel. 2005. Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve. 32:751-760. http://dx.doi.org/10.1002/mus.20425
6. Barton, E.R., B.J. Wang, B.K. Brisson, and H.L. Sweeney. 2010. Diaphragm displays early and progressive functional deficits in dysferlin-deficient mice. Muscle Nerve. 42:22-29. http://dx.doi.org/10.1002/mus.21645
7. Bayless, K.J., G.A. Meininger, J.M. Scholtz, and G.E. Davis. 1998. Osteopontin is a ligand for the alpha4beta1 integrin. J. Cell Sci. 111:1165-1174.
8. Bello, L., A. Kesari, H. Gordish-Dressman, A. Cnaan, L.P. Morgenroth, J. Punetha, T. Duong, E.K. Henricson, E. Pegoraro, C.M. McDonald, and E.P. Hoffman. Cooperative International Neuromuscular Research Group Investigators. 2015. Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study. Ann. Neurol. 77:684-696. http://dx.doi.org/10.1002/ana.24370
9. Belperio, J.A., M. Dy, L. Murray, M.D. Burdick, Y.Y. Xue, R.M. Strieter, and M.P. Keane. 2004. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J. Immunol. 173:4692-4698. http://dx.doi.org/10.4049/jimmunol.173.7.4692
10. Borthwick, L.A., T.A. Wynn, and A.J. Fisher. 2013. Cytokine mediated tissue fibrosis. Biochim. Biophys. Acta. 1832:1049-1060. http://dx.doi.org/10.1016/j.bbadis.2012.09.014
11. Bryer, S.C., G. Fantuzzi, N. Van Rooijen, and T.J. Koh. 2008. Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. J. Immunol. 180:1179-1188. http://dx.doi.org/10.4049/jimmunol.180.2.1179
12. Bushby, K., R. Finkel, D.J. Birnkrant, L.E. Case, P.R. Clemens, L. Cripe, A. Kaul, K. Kinnett, C. McDonald, S. Pandya, et al. DMD Care Considerations Working Group. 2010. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9:77-93. http://dx.doi.org/10.1016/S1474-4422(09)70271-6
13. Byrne, P., P. McGuirk, S. Todryk, and K.H. Mills. 2004. Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. Eur. J. Immunol. 34:2579-2588. http://dx.doi.org/10.1002/eji.200425092
14. Cantini, M., E. Giurisato, C. Radu, S. Tiozzo, F. Pampinella, D. Senigaglia, G. Zaniolo, F. Mazzoleni, and L. Vitiello. 2002. Macrophage-secreted myogenic factors: A promising tool for greatly enhancing the proliferative capacity of myoblasts in vitro and in vivo. Neurol. Sci. 23:189-194. http://dx.doi.org/10.1007/s100720200060
15. Casals, G., J. Ordi, M. Creus, F. Fábregues, R. Casamitjana, L. Quinto, E. Campo, and J. Balasch. 2008. Osteopontin and alphavbeta3 integrin expression in the endometrium of infertile and fertile women. Reprod. Biomed. Online. 16:808-816. http://dx.doi.org/10.1016/S1472-6483(10)60146-0
16. Crane, M.J., J.M. Daley, O. van Houtte, S.K. Brancato, W.L. Henry Jr., and J.E. Albina. 2014. The monocyte to macrophage transition in the murine sterile wound. PLoS One. 9:e86660. http://dx.doi.org/10.1371/journal.pone.0086660
17. Das, R., S. Philip, G.H. Mahabeleshwar, A. Bulbule, and G.C. Kundu. 2005. Osteopontin: Its role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUB MB Life. 57:441-447. http://dx.doi.org/10.1080/15216540500159424
18. Dumont, N., and J. Frenette. 2010. Macrophages protect against muscle atrophy and promote muscle recovery in vivo and in vitro: A mechanism partly dependent on the insulin-like growth factor-1 signaling molecule. Am. J. Pathol. 176:2228-2235. http://dx.doi.org/10.2353/ajpath.2010.090884
19. Ermolova, N.V., L. Martinez, S.A. Vetrone, M.C. Jordan, K.P. Roos, H.L. Sweeney, and M.J. Spencer. 2014. Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function. Neuromuscul. Disord. 24:583-595. http://dx.doi.org/10.1016/j.nmd.2014.04.006
20. Galindo, C.L., J.H. Soslow, C.L. Brinkmeyer-Langford, M. Gupte, H.M. Smith, S. Sengsayadeth, D.B. Sawyer, D.W. Benson, J.N. Kornegay, and L.W. Markham. 2015. Translating golden retriever muscular dystrophy microarray findings to novel biomarkers for cardiac/skeletal muscle function in Duchenne muscular dystrophy. Pediatr. Res. http://dx.doi.org/10.1038/pr.2015.257
21. Gao, C., H. Guo, Z. Mi, M.J. Grusby, and P.C. Kuo. 2007. Osteopontin induces ubiquitin-dependent degradation of STAT1 in RAW264.7 murine macrophages. J. Immunol. 178:1870-1881. http://dx.doi.org/10.4049/jimmunol.178.3.1870
22. Godfrey, D.I., and M. Kronenberg. 2004. Going both ways: Immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114:1379-1388. http://dx.doi.org/10.1172/JCI200423594
23. Goodison, S., V. Urquidi, and D. Tarin. 1999. CD44 cell adhesion molecules. MP, Mol. Pathol. 52:189-196. http://dx.doi.org/10.1136/mp.52.4.189
24. Haslett, J.N., D. Sanoudou, A.T. Kho, R.R. Bennett, S.A. Greenberg, I.S. Kohane, A.H. Beggs, and L.M. Kunkel. 2002. Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc. Natl. Acad. Sci. USA. 99:15000-15005. http://dx.doi.org/10.1073/pnas.192571199
25. Heydemann, A., E. Ceco, J.E. Lim, M. Hadhazy, P. Ryder, J.L. Moran, D.R. Beier, A.A. Palmer, and E.M. McNally. 2009. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J. Clin. Invest. 119:3703-3712. http://dx.doi.org/10.1172/JCI39845
26. Hunt, L.C., A. Upadhyay, J.A. Jazayeri, E.M. Tudor, and J.D. White. 2013. An anti-inflammatory role for leukemia inhibitory factor receptor signaling in regenerating skeletal muscle. Histochem. Cell Biol. 139:13-34. http://dx.doi.org/10.1007/s00418-012-1018-0
27. Kahles, F., H.M. Findeisen, and D. Bruemmer. 2014. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol. Metab. 3:384-393. http://dx.doi.org/10.1016/j.molmet.2014.03.004
28. Koguchi, Y., K. Kawakami, S. Kon, T. Segawa, M. Maeda, T. Uede, and A. Saito. 2002. Penicillium marneffei causes osteopontin-mediated production of interleukin-12 by peripheral blood mononuclear cells. Infect. Immun. 70:1042-1048. http://dx.doi.org/10.1128/IAI.70.3.1042-1048.2002
29. Kramerova, I., E. Kudryashova, J.G. Tidball, and M.J. Spencer. 2004. Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro. Hum. Mol. Genet. 13:1373-1388. http://dx.doi.org/10.1093/hmg/ddh153
30. Kyriakides, T., E. Pegoraro, E.P. Hoffman, L. Piva, S. Cagnin, G. Lanfranchi, R.C. Griggs, and S.F. Nelson. 2011. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy: Predicting the severity of Duchenne muscular dystrophy: Implications for treatment. Neurology. 77:1858-1859. http://dx.doi.org/10.1212/WNL.0b013e318239b9ae
31. Liaw, L., D.E. Birk, C.B. Ballas, J.S. Whitsitt, J.M. Davidson, and B.L. Hogan. 1998. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Invest. 101:1468-1478. http://dx.doi.org/10.1172/JCI2131
32. Liu, Y.C., X.B. Zou, Y.F. Chai, and Y.M. Yao. 2014. Macrophage polarization in inflammatory diseases. Int. J. Biol. Sci. 10:520-529. http://dx.doi.org/10.7150/ijbs.8879
33. Mann, C.J., E. Perdiguero, Y. Kharraz, S. Aguilar, P. Pessina, A.L. Serrano, and P. Muñoz-Cánoves. 2011. Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle. 1:21. http://dx.doi.org/10.1186/2044-5040-1-21
34. Mantovani, A., A. Sica, and M. Locati. 2007. New vistas on macrophage differentiation and activation. Eur. J. Immunol. 37:14-16. http://dx.doi.org/10.1002/eji.200636910
35. McDouall, R.M., M.J. Dunn, and V. Dubowitz. 1990. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J. Neurol. Sci. 99:199-217. http://dx.doi.org/10.1016/0022-510X(90)90156-H
36. Mojumdar, K., F. Liang, C. Giordano, C. Lemaire, G. Danialou, T. Okazaki, J. Bourdon, M. Rafei, J. Galipeau, M. Divangahi, and B.J. Petrof. 2014. Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2. EMBO Mol. Med. 6:1476-1492. http://dx.doi.org/10.15252/emmm.201403967
37. Moorwood, C., M. Liu, Z. Tian, and E.R. Barton. 2013. Isometric and eccentric force generation assessment of skeletal muscles isolated from murine models of muscular dystrophies. J. Vis. Exp. (71):e50036. http://dx.doi.org/10.3791/50036
38. Nakagawa, R., I. Nagafune, Y. Tazunoki, H. Ehara, H. Tomura, R. Iijima, K. Motoki, M. Kamishohara, and S. Seki. 2001. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J. Immunol. 166:6578-6584. http://dx.doi.org/10.4049/jimmunol.166.11.6578
39. Nakano, Y., H. Hisaeda, T. Sakai, H. Ishikawa, M. Zhang, Y. Maekawa, T. Zhang, M. Takashima, M. Nishitani, R.A. Good, and K. Himeno. 2002. Roles of NKT cells in resistance against infection with Toxoplasma gondii and in expression of heat shock protein 65 in the host macrophages. Microbes Infect. 4:1-11. http://dx.doi.org/10.1016/S1286-4579(01)01503-9
40. Naldini, A., D. Leali, A. Pucci, E. Morena, F. Carraro, B. Nico, D. Ribatti, and M. Presta. 2006. Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J. Immunol. 177:4267-4270. http://dx.doi.org/10.4049/jimmunol.177.7.4267
41. Novak, M.L., and T.J. Koh. 2013. Macrophage phenotypes during tissue repair. J. Leukoc. Biol. 93:875-881. http://dx.doi.org/10.1189/jlb.1012512
42. Nyström, T., P. Dunér, and A. Hultgårdh-Nilsson. 2007. A constitutive endogenous osteopontin production is important for macrophage function and differentiation. Exp. Cell Res. 313:1149-1160. http://dx.doi.org/10.1016/j.yexcr.2006.12.026
43. Porter, J.D., S. Khanna, H.J. Kaminski, J.S. Rao, A.P. Merriam, C.R. Richmonds, P. Leahy, J. Li, W. Guo, and F.H. Andrade. 2002. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophindeficient mdx mice. Hum. Mol. Genet. 11:263-272. http://dx.doi.org/10.1093/hmg/11.3.263
44. Rigamonti, E., P. Zordan, C. Sciorati, P. Rovere-Querini, and S. Brunelli. 2014. Macrophage plasticity in skeletal muscle repair. BioMed Res. Int. 2014:560629. http://dx.doi.org/10.1155/2014/560629
45. Rollo, E.E., and D.T. Denhardt. 1996. Differential effects of osteopontin on the cytotoxic activity of macrophages from young and old mice. Immunology. 88:642-647. http://dx.doi.org/10.1046/j.1365-2567.1996.d01-691.x
46. Rollo, E.E., D.L. Laskin, and D.T. Denhardt. 1996. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J. Leukoc. Biol. 60:397-404.
47. Saclier, M., H. Yacoub-Youssef, A.L. Mackey, L. Arnold, H. Ardjoune, M. Magnan, F. Sailhan, J. Chelly, G.K. Pavlath, R. Mounier, et al. 2013. Differentially activated macrophages orchestrate myogenic precursor cell fate during human skeletal muscle regeneration. Stem Cells. 31:384-396. http://dx.doi.org/10.1002/stem.1288
48. Sicinski, P., Y. Geng, A.S. Ryder-Cook, E.A. Barnard, M.G. Darlison, and P.J. Barnard. 1989. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 244:1578-1580. http://dx.doi.org/10.1126/science.2662404
49. Slifka, M.K., R.R. Pagarigan, and J.L. Whitton. 2000. NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells. J. Immunol. 164:2009-2015. http://dx.doi.org/10.4049/jimmunol.164.4.2009
50. Song, E., N. Ouyang, M. Hörbelt, B. Antus, M. Wang, and M.S. Exton. 2000. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell. Immunol. 204:19-28. http://dx.doi.org/10.1006/cimm.2000.1687
51. Suelves, M., B. Vidal, A.L. Serrano, M. Tjwa, J. Roma, R. López-Alemany, A. Luttun, M.M. de Lagrán, A. Díaz-Ramos, M. Jardí, et al. 2007. uPA deficiency exacerbates muscular dystrophy in MDX mice. J. Cell Biol. 178:1039-1051. http://dx.doi.org/10.1083/jcb.200705127
52. To, W.S., and K.S. Midwood. 2011. Plasma and cellular fibronectin: Distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair. 4:21. http://dx.doi.org/10.1186/1755-1536-4-21
53. Varga, T., R. Mounier, P. Gogolak, S. Poliska, B. Chazaud, and L. Nagy. 2013. Tissue LyC6- macrophages are generated in the absence of circulating LyC6- monocytes and Nur77 in a model of muscle regeneration. J. Immunol. 191:5695-5701. http://dx.doi.org/10.4049/jimmunol.1301445
54. Vetrone, S.A., E. Montecino-Rodriguez, E. Kudryashova, I. Kramerova, E.P. Hoffman, S.D. Liu, M.C. Miceli, and M.J. Spencer. 2009. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J. Clin. Invest. 119:1583-1594. http://dx.doi.org/10.1172/JCI37662
55. Vidal, B., A.L. Serrano, M. Tjwa, M. Suelves, E. Ardite, R. De Mori, B. Baeza-Raja, M. Martínez de Lagrán, P. Lafuste, V. Ruiz-Bonilla, et al. 2008. Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev. 22:1747-1752. http://dx.doi.org/10.1101/gad.465908
56. Villalta, S.A., H.X. Nguyen, B. Deng, T. Gotoh, and J.G. Tidball. 2009. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum. Mol. Genet. 18:482-496. http://dx.doi.org/10.1093/hmg/ddn376
57. Villalta, S.A., B. Deng, C. Rinaldi, M. Wehling-Henricks, and J.G. Tidball. 2011a. IFN-γ promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation. J. Immunol. 187:5419-5428. http://dx.doi.org/10.4049/jimmunol.1101267
58. Villalta, S.A., C. Rinaldi, B. Deng, G. Liu, B. Fedor, and J.G. Tidball. 2011b. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum. Mol. Genet. 20:790-805. http://dx.doi.org/10.1093/hmg/ddq523
59. Weber, G.F., S. Zawaideh, S. Hikita, V.A. Kumar, H. Cantor, and S. Ashkar. 2002. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J. Leukoc. Biol. 72:752-761.
60. Wehling, M., M.J. Spencer, and J.G. Tidball. 2001. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J. Cell Biol. 155:123-131. http://dx.doi.org/10.1083/jcb.200105110
61. Wermuth, P.J., and S.A. Jimenez. 2015. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin. Transl. Med. 4:2. http://dx.doi.org/10.1186/s40169-015-0047-4
62. Yogo, Y., S. Fujishima, T. Inoue, F. Saito, T. Shiomi, K. Yamaguchi, and A. Ishizaka. 2009. Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis. Respir. Res. 10:80. http://dx.doi.org/10.1186/1465-9921-10-80